Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants

RSV is the most common cause of infant respiratory infections, including pneumonia

- PMLiVE

Moderna and Life Edit partner to accelerate gene editing therapies

The companies will jointly develop in vivo mRNA therapies for hard-to-treat diseases

- PMLiVE

Rare and Orphan Diseases

Why we need authentic and personalised communications in the evolving rare disease space. By Sarah Mikhailov, Managing Director, Brand at Havas Life Medicom

Havas Life London

- PMLiVE

In uncertain times, plan for the actions you may never take

To be successful in changeable times, we must elevate the way we create our brand plans

- PMLiVE

Pfizer’s maternal RSV vaccine candidate accepted for FDA priority review

Globally, RSV infections cause over 100,000 child deaths annually

- PMLiVE

UK government commissions independent review into clinical trials

The last five years have seen a 44% drop in commercial clinical trial recruitment in the UK

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

EU flag

EC approves first gene therapy for adults with haemophilia B

Typically, haemophilia B patients must adhere to strict, lifelong IV infusion schedules

- PMLiVE

Life sciences reimagined

Reassessing future priorities in the wake of the pandemic

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

- PMLiVE

BMS reports positive three-year results for Opdivo to treat bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

NICE publishes final draft guidance recommending three COVID-19 treatments

The medicines have shown promise in treating COVID-19 and been found cost-effective

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links